IsoTis OrthoBiologics, Inc. Accell Connexus [™] DBM Putty 510(k) Premarket Notification

February 2006

MAR 2 7 2006

510(k) Summary for IsoTis OrthoBiologics, Inc. Accell Connexus DBM Putty

1. **SPONSOR**

IsoTis OrthoBiologics, Inc. 2 Goodyear, Suite B Irvine, CA 92618 U.S.A

Contact Person:

Eliane Schutte

Telephone:

+31-(0) 30-2295253

Facsimile:

+31-(0) 30-2280255

Date Prepared:

February 03, 2006

2. **DEVICE NAME**

Proprietary Name:

Accell Connexus Demineralized Bone Matrix Putty

Regulation Name:

Human Bone Graft Material

Regulatory Class: Product Code:

11 NUN

3. PREDICATE DEVICE

DynaGraft II Dental (Demineralized Bone Matrix) [K043573]

DEVICE DESCRIPTION 4.

Accell Connexus[™] DBM Putty is derived from selected donated human bone tissue that has been processed into particles. The bone particles are subsequently demineralized using a hydrochloric acid process. The demineralized bone matrix (DBM) is combined with a reverse phase carrier and formulated to a paste or putty-like consistency.

Accell Connexus DBM Putty is osteoconductive and osteoinductive bone filling material. The osteoinductive potential is demonstrated in athymic mouse model.


5. INTENDED USE

Accell Connexus[™] DBM Putty is a bone filling material indicated for augmentation or reconstructive treatment of alveolar ridge. This includes:

- Filling of defects after root resection, apicoectomy and cystectomy
- Filling of extraction sockets to enhance preservation of the alveolar ridge
- Elevation of maxillary sinus floor
- Treatment of periodontal defects

6. TECHNOLOGICAL CHARACTERISTICS AND SUBSTANTIAL EQUIVALENCE

Accell Connexus DBM Putty is substantially equivalent to DynaGraft II Dental Putty previously cleared by FDA under 510(k) K043573. Both products utilize



IsoTis OrthoBiologics, Inc.
Accell Connexus DBM Putty 510(k) Premarket Notification

February 2006

ground, human donor cortical demineralized bone for the product. Both products utilize an inactive poloxamer reverse phase carrier (RPM) as a containing agent to provide the product's putty-like consistency and handling characteristics. The proposed device and predicate device have the same indications for use, provided sterile and for single patient. The main difference between the two products is that Accell Connexus DBM Putty contains more demineralized bone by weight and volume and less synthetic carrier.

7. PERFORMANCE DATA

Product safety and effectiveness is adequately supported by the substantial equivalence information, materials data, and animal test results provided in this Premarket Notification.



MAR 2 7 2006

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Isotis NV
Ms. Elaine Schutte
Director of Regulatory Affairs
Isotis Orthobiologics, Incorporated
2 Goodyear, Suite B
Irvine, California 92618

Re: K060306

Trade/Device Name: Accell Connexus Demineralized Bone Matrix Putty

Regulation Number: 872.3930

Regulation Name: Bone Graft Material

Regulatory Class: II Product Code: NUN Dated: February 6, 2006 Received: February 7, 2006

Dear Ms. Schutte:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent [(for the indications for use stated in the enclosure)] to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to continue marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally Part 809.10 for <u>in vitro</u> diagnostic devices), please contact the Office of Compliance at (301) 594-4613. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at their toll free number (800) 638-2041 or at (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html.

Sincerely yours,

Chiu Lin, Ph.D

Director

Division of Anesthesiology, General Hospital, Infection Control and Dental Devices

Office of Device Evaluation

Center for Devices and Radiological Health.

Enclosure

February 2006

4 INDICATIONS FOR USE STATEMENT

Indications for Use

510(k) Number (if Known):

Device Name: Accell Connexus Demineralized Bone Matrix Putty

Indications for Use:

Accell Connexus[™] DBM Putty is a bone filling material indicated for augmentation or reconstructive treatment of alveolar ridge. This includes:

- Filling of defects after root resection, apicoectomy and cystectomy
- Filling of extraction sockets to enhance preservation of the alveolar ridge
- Elevation of maxillary sinus floor
- Treatment of periodontal defects

Prescription Use X (Part 21 CFR 801 Subpart D) AND/OR

Over-The-Counter Use ___ (21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)